Therapy | Docetaxel + Hormonal Therapy | Docetaxel – Single Treatment | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Author year | Current series | Narita 2012 | Kim 2011 | Mellado 2009 | Sella 2008 | Chi 2008 | Prayer-Galetti 2007 | Hussain 2003 | Magi-Galuzzi 2007 | Febbo 2005 | Dreicer 2004 |
Patients (n) | 30 | 18 | 24 RP/Rad | 57 | 22 | 72 | 22 | 21 | 29 | 19 | 29 |
Docetaxel (D) Regime | 3 cycles, q21, (75 mg/m2) | 6 weeks, q7, (30 mg/m2) | 3 cycles, q7 (3xD +1 week rest) (36 mg/m2) | 3 cycles, q7 (3xD +1 week rest) (36 mg/m2) | 4 cycles, q21 (70 mg/m2) | 3 cycles, q7 (6xD +2 weeks rest) (35 mg/m2) | 4 cycles, q21, (70 mg/m2) | 6 cycles, q21 (70 mg/m2) | 6 weeks, q7, (40 mg/m2) | 6 months, q7, (36 mg/m2) | 6 weeks, q7, (40 mg/m2) |
LHRH Analog | buserelin 9.45 mg (1x3 months) | leuprorelin 11.25 mg (2x3 months) | n.d. | goserelin 10.8 mg (1x3 months) | goserelin 3.6 mg (3x1 month) | buserelin 6.6 mg (3x2 months) | triptorelin 3.75 mg (4–12 months) | n.d. | n.d. | n.d. | n.d. |
Antiandrogens | bicaluta-mide 50 mg/d (9 weeks) | bicaluta-mide 81 mg/d (12 weeks) | n.d. | flutamide 750 mg/d (12 weeks) | bicaluta-mide 50 mg/d (12 weeks) | flutamide 750 mg/d // bicaluta-mide 50 mg/d (4 weeks) | n.d. | n.d. | n.d. | n.d. | n.d. |
Estramustine | n.d. | 1120 mg/d (6 weeks) | 420 mg/d for 3d | n.d. | 840 mg/d for 5d | n.d. | 600 mg/m2 (12 weeks) | 840 mg/d for 3d | n.d. | n.d. | n.d. |
Therapy-weeks | 9 | 6 | 12 | 12 | 12 | 24 | 16-60 | 18 | 6 | 24 | 6 |
pCR (%) | 0 | 11.1 | 0 | 6 | 0 | 3.1 | 5 | 0 | 0 | 0 | 0 |
pMRD (%) | 3.33 | n.d. | n.d. | 6 | n.d. | 25 | 31.6* | n.d. | n.d. | n.d. | 7.14 |
iPSA, median, range (ng/ml) | 25.8 | 25.8 | 22.3 | 9.7 | 21.2 | 10.8 | 41 | 16.1 | n.d. | n.d. | 12 |
2.1-293 | 5.1-45.1 | 0.3-255 | 0.6-90.8 | 3.2-71.6 | 1.6-65.6 | n.d. | 2.4-175 | 2.5-43.3 | |||
iGl. sc. ≥7 (%) | 90 | 87.4 | 100 | 95 | n.d. | 91 | 86 | 96 | 93 | 75 | 94 |
≥cT3 (%) | 93.3 | 43.8 | 27 | 28 | 64 | 39 | 86 | 25 | 17.8 | 16 | 27 |
≥pT3 (%) | 56.5 | 38.9 | 72.7 | 37 | 36.4 | 44 | 42 | 70 | 82.1 | 62 | 89 |
SVI (%) | 53.3 | 11.1 | 45.5 | n.d. | 40.9 | 22 | 37 | 60 | 39.3 | 50 | 32 |
R0 (%) | 66.7 | 100 | 63.6 | 64.7 | 72.7 | 73 | 74 | 70 | 75 | n.d. | 96 |
pN1 (%) | 36.7 | 22.2 | n.d. | 3.9 | 18.1 | 6 | 21 | 10 | 14.3 | 0 | 14 |
FU, median, range (months) | 48.6 | 18 | 24 | 35 | 23.6 | 42.7 | 53 | 13.1 | 49.5 | 26.5 | 23 |
20-88 | 1-49 | n.d. | 23-47 | 12-55 | 26-66 | 30-64 | 9-18 | 23-72 | 4.5-40 | 1.5-36 | |
Recur. Pts. (%) | 55.2 | 22.2 | 55 | 35.1 | 45.4 | 30.0 | 58.0 | 29.0 | 57.0 | 63.2 | 29.0 |